




William N. Hait, M.D., Ph.D.
SU2C Scientific Advisory Committee



William N. Hait, M.D., Ph.D.

Executive Vice President, Johnson & Johnson
Emeritus, Stand Up To Cancer Scientific Advisory Committee
New Brunswick, NJ

William N. Hait, M.D., Ph.D. is Executive Vice President, Chief External Innovation and Medical Officer for Johnson & Johnson and a member of the Johnson & Johnson Executive Committee. In this role, Bill is responsible for leading external sourcing and

creation of transformational innovation to help Johnson & Johnson achieve its mission to improve human health. He oversees the Research and Development Management Committee that focuses on talent development and best-practice sharing within the Company's R&D community as well as Company efforts to meet its obligations around product safety and ethical research.

Prior to this role, Hait served as Global Head, Johnson & Johnson External Innovation, where he built an enterprise-wide external R&D pipeline, creating innovative solutions utilizing the Company's excellence in pharmaceuticals, medical devices, and consumer products. His team identified disruptive technologies and cutting-edge early innovations in disease areas of emphasis at Johnson & Johnson to eliminate disease through prevention, interception, and cures.

Hait joined Johnson & Johnson in 2007 and was the Global Therapeutic Area Head, Oncology, from 2009 to 2011. He served as Global Head, Janssen R&D from 2011 through 2017 and as interim head in 2022 - 2023.

Before joining J&J, he was the founding Director of the (Rutgers) Cancer Institute of New Jersey, which he led to receive the National Cancer Institute's highest designation of Comprehensive Cancer Center in 2002. From 1993 to 2007 he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey — Robert Wood Johnson Medical School.

After earning his B.A. from the University of Pennsylvania, Hait received his M.D. and Ph.D. (Pharmacology) cum laude from the Medical College of Pennsylvania, where he was elected to Alpha Omega Alpha. He joined the Yale University School of Medicine faculty in 1984 and became Associate Professor of Medicine and Pharmacology, Chief of the Division of Medical Oncology,

Associate Director of the Yale University Comprehensive Cancer Center, Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit. Hait is Board Certified in Internal Medicine and Medical Oncology.

Hait has devoted his time to numerous advisory and editorial boards. He was Editor-in-Chief of Clinical Cancer Research and Associate Editor of Cancer Research, served as President of the American Association for Cancer Research from 2007 – 2008 and currently serves as Treasurer. He has served on various committees for the American Association of Cancer Research (Chair, Clinical Cancer Research Committee), the American Society of Clinical Oncology, the Association of American Cancer Institutes (Board of Directors) and the National Cancer Institute Board of Scientific Advisors.

He currently is a member of the Rutgers Cancer Institute of New Jersey Director's Advisory Board, Board of External Advisors for the Dana Farber/Harvard Cancer Center, The Board of Directors of Research!America, the Vanderbilt University Biomedical Science Advisory Board, and the National Academy of Medicine's President's Advisory Council on Healthy Longevity.